Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) shares saw strong trading volume on Friday . 1,147,349 shares changed hands during mid-day trading, a decline of 1% from the previous session’s volume of 1,154,353 shares.The stock last traded at $42.6360 and had previously closed at $40.36.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the stock. Mizuho raised their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Stifel Nicolaus assumed coverage on shares of Enliven Therapeutics in a report on Tuesday. They issued a “buy” rating and a $60.00 price objective on the stock. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.50.
View Our Latest Research Report on Enliven Therapeutics
Enliven Therapeutics Trading Up 11.7%
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. Analysts anticipate that Enliven Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.
Insider Buying and Selling
In related news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. This trade represents a 16.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Enliven Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Enliven Therapeutics by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after acquiring an additional 1,693 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Enliven Therapeutics by 61.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after acquiring an additional 80,506 shares in the last quarter. Jane Street Group LLC acquired a new stake in Enliven Therapeutics during the 1st quarter worth $578,000. Legal & General Group Plc raised its stake in Enliven Therapeutics by 52.2% during the 2nd quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock worth $646,000 after acquiring an additional 11,058 shares in the last quarter. Finally, Quantbot Technologies LP raised its stake in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
- ERock IPO: A $1.3B Power Play Solution
- The AI Boom Has a Hidden Winner—And It’s Not Nvidia
- SMX: Can Molecular Tracking Technology Become the Next Moonshot?
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
